default author photo

Ayae Nishiyama

National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development

1-23-1 Toyama Shinjuku Yokyo

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

109

TOTAL CITATIONS

1

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Reduced Resistance of SARS-CoV-2 Variants Toward Affinity-Matured Serological Immunity

Number of pages: 58 Posted: 21 Apr 2021
Saya Moriayma, Yu Adachi, Takashi Sato, Keisuke Tonouchi, Lin Sun, Shuetsu Fukushi, Souichi Yamada, Hitomi Kinoshita, Kiyoko Nojima, Takayuki Kanno, Minoru Tobiume, Keita Ishijima, Yudai Kuroda, Park Eunsil, Taishi Onodera, Takayuki Matsumura, Tomohiro Takano, Kazutaka Terahara, Masanori Isogawa, Ayae Nishiyama, Ai Kawana-Tachikawa, Masaharu Shinkai, Natsuo Tachikawa, Shigeki Nakamura, Takahiro Okai, Kazu Okuma, Tetsuro Matano, Tsuguto Fujimoto, Ken Maeda, Makoto Ohnishi, Takaji Wakita, Tadaki Suzuki and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Immunology, National Institute of Infectious Diseases - Department of Virology I, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - AIDS Research Center, Tokyo Shinagawa Hospital, Yokohama Municipal Citizen's Hospital - Division of Infectious Disease, Tokyo Medical University, affiliation not provided to SSRN, National Institute of Infectious Diseases, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Department of Bacteriology I, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Pathology and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 43 (1,145,425)

Abstract:

Loading...

2.

Gene Expression Analysis during The Conversion from a Viable but Nonculturable to Culturable State In Vibrio Cholerae

Number of pages: 29 Posted: 30 Nov 2022
Alafate Ayibieke, Ayae Nishiyama, Mitsutoshi Senoh and Takashi Hamabata
National Center for Global Health and Medicine, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases and National Center for Global Health and Medicine
Downloads 34 (1,263,436)

Abstract:

Loading...

Viable but non-culturable cell, Vibrio cholerae, catalase-induced conversion, gene expression, RNA microarray

3.

Distinct Immune Cell Dynamics Correlate with the Immunogenicity and Reactogenicity of SARS-CoV-2 mRNA Vaccine

Number of pages: 71 Posted: 04 Nov 2021
Tomohiro Takano, Miwa Morikawa, Yu Adachi, Kiyomi Kabasawa, Nicolas Sax, Saya Moriayma, Lin Sun, Masanori Isogawa, Ayae Nishiyama, Taishi Onodera, Kazutaka Terahara, Keisuke Tonouchi, Masashi Nishimura, Kentaro Tomii, Kazuo Yamashita, Takayuki Matsumura, Masaharu Shinkai and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, KOTAI Biotechnologies, Inc., National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Advanced Industrial Science and Technology (AIST) - Artificial Intelligence Research Center (AIRC), KOTAI Biotechnologies, Inc., National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 32 (1,290,922)
Citation 1

Abstract:

Loading...

SARS-CoV-2, Vaccine, Reactogenicity, immune correlates